Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
about
Repurposing metformin for cancer treatment: current clinical studiesTargeting the mTOR pathway in hepatocellular carcinoma: current state and future trendsPathways and therapeutic targets in melanomaMetformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage InfiltrationIsoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cellsUse of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activationEffects of metformin on retinoblastoma growth in vitro and in vivo.Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor GrowthAnti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1.Targeting AMPK for cancer prevention and treatment.Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation.Metformin: a modulator of bevacizumab activity in cancer? A case report2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells.Combined regimen of photodynamic therapy mediated by Gallium phthalocyanine chloride and Metformin enhances anti-melanoma efficacyTargeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression.Metformin - For the dermatologist.ER stress: Autophagy induction, inhibition and selection.Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy.Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin.AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.Potential applications for biguanides in oncologyPhenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells.Paradoxic effects of metformin on endothelial cells and angiogenesis.Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.Metformin in dermatology: an overview.Vemurafenib in melanoma.Metformin in lung cancer: rationale for a combination therapy.Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates.Is it time to test biguanide metformin in the treatment of melanoma?Immunogenic, cellular, and angiogenic drivers of tumor dormancy--a melanoma view.Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation.Metformin is synthetically lethal with glucose withdrawal in cancer cells.Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal CancerEffects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.Functional Analysis of Dual-Specificity Protein Phosphatases in Angiogenesis.
P2860
Q26752651-9E413FF8-7ED5-4DDB-A06E-871EF0C9B120Q26830194-1BBEC30F-81E7-4812-9310-4186CBCDC1F2Q26865736-84C50D93-C7E6-4EF0-BF7B-F62338099F13Q27853104-9E20ED49-6DDB-4DE5-A9CE-E5CD1DE927F2Q28550667-F67ED0C8-3203-4D14-A6FB-3E0490463E65Q28817206-0A2CE85B-789B-40FB-A198-C1D72DB65C05Q33645356-62D30276-2FDA-4A08-AFBC-5431BF3F50D1Q34432841-E31B6B0C-08A5-4158-BBE6-4DE6C1428C92Q35035126-365D3F03-D163-4F0F-8CC7-0B71BABCEF14Q35251663-9048C533-7322-4988-815C-7381CA43F162Q35580483-DA714128-B47B-49F8-8E0B-722896A0BC65Q35781311-7930E219-56EF-4FB8-962E-B95939165873Q36016760-C40C312F-CCB6-4DE4-A8FB-74AF331EB335Q36214971-5E9D4667-0272-4AB9-A689-65A33DF1C4CDQ36235609-6EE6763E-3E28-46BE-A2A7-BAB0E64CA8CAQ36302221-D7BA564F-BB55-4599-AE1E-7C86CAD7E0DBQ36545721-F399C0D3-44C4-4AD4-BC99-19AE93F68390Q36651435-E95891F4-CCF6-4E9B-823A-E674908D5FDAQ36777229-30D459AC-4EE6-452F-B313-F74C255F8F3BQ37011502-D3408C19-EB54-49E8-BCB6-51B936BE6995Q37015746-E2FD9E3C-DD7E-4E0B-ADEA-CD521AB91122Q37086032-D0331C9C-6983-49FE-8FD2-2AC5E78E6518Q37123877-A5AFB469-EB96-4DB5-A671-6404AE1CB0F6Q37318124-FA4A3519-0E7B-49C5-8AEA-739C32409D10Q37482888-52AF720B-D733-48BF-8C57-F83332811C3AQ37690270-A0A754BE-E12B-4BB7-82F7-1AF3EAD14C01Q37731504-F803FFE8-1E9C-4718-A0E9-0FEB4CAF3901Q38068205-0EAA5A46-E0A9-4536-935E-125B7747C167Q38084323-5C3F895F-D8E7-4474-B47E-01BBFF53B546Q38101603-0F148EB7-1B9B-4F40-8133-EFF8DA5AAF6CQ38128357-2D76FD10-25B4-4E11-87B0-2F8A67D0A953Q38147841-73E9B77A-A09B-48C7-9E57-E84E46E23F25Q38215034-2863F728-5262-44F1-8314-3BFF8DF9A497Q38619615-566D110E-90FB-4536-B0E7-CE8EA48038F4Q38766321-1CD916C9-50DD-4B5D-93BB-FC60684A61C4Q39312255-F283128A-B2E8-44E7-9603-47B60826C2A9Q39378337-11950FB8-9FBA-4F4A-9871-6A8403F3EDC3Q39519100-4CC44E7E-A6E5-489A-9561-894ED81F2F24Q40380730-DB0A89AB-BB28-460E-886A-5AAE711A0D58Q40579475-E0540F25-9010-48C8-9CFB-A286FF4A57B3
P2860
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
@ast
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
@en
type
label
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
@ast
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
@en
prefLabel
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
@ast
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
@en
P2093
P2860
P1433
P1476
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
@en
P2093
Amaya Viros
Matthew J Martin
Robert Hayward
P2860
P304
P356
10.1158/2159-8290.CD-11-0280
P577
2012-03-31T00:00:00Z